Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes

Applied Health Economics and Health Policy

Volumn 12, Issue 2, 2014, Pages 179-190

  Oglesby, Alan ^a   Korves, Caroline ^b   Laliberté, François ^b,c   Dennis, Gregory ^a   Rao, Sapna ^b   Suthoff, Ellison Dial ^b   Wei, Robert ^b   Duh, Mei Sheng ^b  

^a GLAXOSMITHKLINE   (United States)

^b ANALYSIS GROUP   (United States)

^c Groupe d analyse   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ALGORITHM; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DELAYED DIAGNOSIS; DISEASE ACTIVITY; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRODROMAL SYMPTOM; PROPENSITY SCORE; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; COHORT ANALYSIS; COMPARATIVE STUDY; COST; ECONOMICS; HEALTH INSURANCE; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; COHORT STUDIES; COSTS AND COST ANALYSIS; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84899125274     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0085-x     Document Type: Article

References (28)

1. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum. 1999;42(9):1785-96.
2. How is lupus diagnoses. Lupus Foundation of America, Inc. http://www.lupus.org/answers/entry/diagnosing-lupus. Accessed 17 Dec 2013.
3. Doria A, Zen M, Canova M, Bettio S, Bassi N, Nalotto L, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev. 2010;10(1):55-60 Epub 2010 Sep 8.
4. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL. Systemic lupus erythematosus: survival patterns. Experience with 609 patients. JAMA. 1981;245:934-8. (Pubitemid 11154415)
5. Cervera R, Khamashta MA, Font J, et al. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine. 1993;72:113-24. (Pubitemid 23097765)
6. Ozbek S, Sert M, Paydas S, Soy M. Delay in the diagnosis of SLE: the importance of arthritis/arthralgia as the initial symptom. Acta Med Okayama. 2003;57(4):187-90. (Pubitemid 37386875)
7. Li T, Carls GS, Panopalis P, et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum. 2009;61:755-63.
8. Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008;59:1788-95.
9. Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med. 2009;51:66-79.
10. Yelin E, Trupin L, Katz P, et al. Impact of health maintenance organizations and fee-for-service on health care utilization among people with systemic lupus erythematosus. Arthritis Rheum. 2007;57:508-15. (Pubitemid 46682541)
11. Pelletier EM, Ogale S, Yu E, et al. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther. 2009;31:2653-64.
12. Furst DE, Clarke A, Fernandes AW, et al. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. Lupus. 2013;22(3):268-78.
13. Chibnik LB, Massarotti EM, Costenbader KH. Identification and validation of lupus nephritis cases using administrative data. Lupus. 2010;19(6):741-3.
14. Hahn B, Singh R. Animal models of SLE. In: Wallace DJ, Hahn BH, editors. Dubois' Lupus Erythematosus 7th ed. 2007;p. 299-355.
15. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33(8):1563-9. (Pubitemid 44168828)
16. Garris CP, Jhingran PM, Engel-Nitz NM, et al. Assessing systemic lupus erythematosus disease severity and disease flares: development of a claims-based algorithm. Arthritis Rheum. 2010;62 Suppl:757.
17. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-9. (Pubitemid 41587600)
18. Mayo Clinic. Lupus complications. http://www.mayoclinic.com/health/lupus/ DS00115/DSECTION=complications. Accessed 17 Dec 2013.
19. Alliance for Lupus Research. Cardiovascular disease and lupus. http://www.lupusresearch.org/research/acr/cardiovascular.html. Accessed 17 Dec 2013.
20. Bhatt SP, Handa R, Gulati GS, et al. Peripheral vascular disease in systemic lupus erythematosus. Lupus. 2007;16:720-3. (Pubitemid 47517867)
21. Keane MP, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax. 2000;55:159-66. (Pubitemid 30245959)
22. Sen D, Keen RW. Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus. 2001;10:227-32. (Pubitemid 32410083)
23. Appenzeller S, Pallone AT, Natalin RA, Costallat LT. Prevalence of thyroid dysfunction in systemic lupus erythematosus. J Clin Rheumatol. 2009;15:117-9.
24. Pyne D, Isenberg DA. Autoimmune thyroid disease in systemic lupus erythematosus. Ann Rheum Dis. 2002;61:70-2. (Pubitemid 34074845)
25. Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 1999;26:2137-43. (Pubitemid 29487006)
26. Doria A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119:700-6. (Pubitemid 44128446)
27. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rhematol. 1994;21(11):2046-51. (Pubitemid 24352349)
28. Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II: Role of clinical, immunological and psychological determinants. Rheumatology. 2004;43:1580-6. (Pubitemid 39642587)